Ascendia Pharmaceuticals, a start-up specialty pharmaceutical company in the business of providing formulation technologies and product development services for poorly soluble molecules, announced that the company has successfully applied its nano-emulsion technology platform to a novel injectable formulation of clopidogrel- the world’s top-selling blood thinner medicine. Ascendia has advanced the program to pre-IND development stage, and has filed US and worldwide PCT patent applications on the product.
“There is a significant unmet medical need for a parenteral clopidogrel dosage form for the treatment of Acute Coronary Syndrome under life-threatening situations,” said Jingjun “Jim” Huang, CEO of Ascendia. “With our nano-emulsion platform technology, Ascendia has demonstrated that a ready-to-use, stable and soluble, parenteral form of clopidogrel is both technically and commercially feasible- by addressing the solubility, physical and chemical stability, API sourcing, manufacturing, and delivery challenges of this difficult compound.”
Ascendia was founded in 2012 by Huang and has its commercial operations in North Brunswick, New Jersey.
ASD-002 is a parenteral form of clopidogrel formulated as an oil-in-water nano-emulsion suspension. Ascendia is developing ASD-002 for the treatment of Acute Coronary Syndrome, which refers to either unstable angina or when blood supply to the coronary arteries becomes suddenly fully or partially blocked (i.e., a myocardial infarction).
Date: September 4, 2014
Source: Ascendia
